Interferon-gamma (IFNg) treatment is deleterious in multiple sclerosis (MS). MS occurs twice as frequently in women as in men. IFNg expression varies by gender. We studied a population-based sample of US MS patients and ethnicity-matched controls and independent Northern Irish and Belgian hospital-based patients and controls for association with MS, stratified by gender, of an intron 1 microsatellite [I1 (761) 
Introduction
Multiple sclerosis (MS) is a complex disease with genetic and environmental influences on susceptibility 1,2 and possibly on the course of disease. 3 Most susceptibility loci, except perhaps the major histocompatibility complex, contribute only a small effect. [4] [5] [6] [7] [8] Association studies are powerful methods to uncover relatively small effects of allelic variants on complex traits. 9 Interferon-gamma (IFNg) stimulates Th-1 clonal expansion and inhibits Th-2 expansion. The balance between Th-1 and Th-2 CD4 cells is relevant to autoimmunity and to MS. 10, 11 IFNg expression is increased in experimental allergic encephalomyelitis (EAE) 12 and parallels disease severity. 13 However, it is unclear whether the increased IFNg expression is a deleterious or a disease limiting response in EAE, as IFNg receptor knockout mice are more susceptible to EAE than wild-type mice. 14, 15 Transgenic mice overexpressing IFNg in the central nervous system under the control of an oligodendrocyte-specific promoter develop extensive primary demyelination compared to wild-type mice. 16, 17 IFNg may exert deleterious effects directly on myelinating cells and also through activation of macrophages and microglia. 18 IFNg also induces dendritic retraction and inhibits synapse formation. 19 IFNg expression increases in the 2 weeks preceding attacks of MS. 20, 21 Low levels of IFNg expression by lymphocytes at the initiation of treatment with IFNb predict a favorable response to treatment. 22 Treatment with exogenous IFNg is deleterious to patients with MS. 23 However, as is the case in EAE, whether endogenous IFNg expression represents a deleterious or a disease limiting effect in MS is unknown. Genetic variants that affect expression or function of IFNg might favorably or unfavorably influence the susceptibility to and course and severity of MS.
Men develop MS one-third as often as women. While many factors have been invoked to explain the difference in susceptibility to MS between men and women, the reasons are not understood. 24 Whether there are genomic differences that account for reduced susceptibility in men is unknown. Men also have a higher frequency of primary progressive and lower frequency of bout-onset (relapsing-remitting and secondary progressive) disease course compared to women. 25 Pelfrey et al 26 demonstrated that PLP-induced IFNg secretion was higher in women than men in both patients with MS and controls. The percentage of IFNg-producing CD3 cells correlates with disease severity in women but not in men. 27 The IFNg gene (IFNG) is located on chromosome 12q14-15 28 and is comprised of four exons. A rare polymorphism in the promoter, 29 a dinucleotide repeat polymorphism in intron 1 [I1(761)*CA n ] 30 and a polymorphism in the 3 0 untranslated (UTR) region 31 were previously reported. Recently, multiple promoter polymorphisms, a T insertion in intron 1, multiple polymorphisms in intron 3 and exon 4 as well as in 3 0 UTR have been reported. [32] [33] [34] [35] [36] Some of these polymorphisms are predominately described in African or AfricanAmerican populations. [34] [35] [36] Several groups have studied the association of the intron 1 dinucleotide polymorphism with MS. [37] [38] [39] [40] [41] Certain authors of this study (KV, AG) previously reported excess parental transmission of the I1(761)*CA 13 allele to Sardinian men with MS who did not carry the HLA DR 3 and 4 alleles. 39 They have recently extended the study to eight additional microsatellite markers within the region. The association in the region was confined to the 118-kilobase interval limited by the centromeric marker D12S313 and the telomeric marker D12S2511, an interval in which IL26 and IFNG are the only genes. 42 In a preliminary study, we had independently screened the promoter region, exons, splice sites and 3 0 region of IFNG for polymorphisms in a population-based sample in Olmsted County, MN. We showed that the G allele of a novel single-nucleotide polymorphism (SNP) [3 0 (325)*G-A], which was just downstream of the 3 0 UTR and in significant linkage disequilibrium (LD) with the I1(761)*CA 12 allele, was under-represented in men compared to women with MS. 43 In the present study, we sought to confirm the association between IFNG polymorphisms and susceptibility to MS in men, using a larger population-based sample of patients from Olmsted County, MN, and two other populations from Northern Ireland and Belgium.
Results
The demographics of the hospital-based patients with MS from Northern Ireland and Belgium were similar to the population-based sample of patients from USA (Table 1) . There were differences in the ratio of women to men in the patient populations (2.5 in MN, 1.9 in Northern Ireland and 1.5 in Belgium). The age of onset of MS did not differ between populations and between men and women. The frequency of patients with bout-onset disease was lower in the Northern Irish population (326 of 432, 75.5%) compared to USA (198 of 221, 89.6%) (Po0.001) and Belgium (187 of 208, 89.9%) (Po0.001). Men in all three populations had bout-onset disease less frequently than women.
The genetic markers considered in this study are illustrated in Figure 1 . Hardy-Weinberg equilibrium (HWE) was evaluated by site in controls for men and women separately. In men, marker D12S313 in the USA population, marker D12S2511 in the Belgium population and marker I1(761)*CA n in the Northern Irish population deviated from HWE. In women, markers D12S313 and D12S2511 in the USA population and marker I1(761)*CA n in the Northern Irish population deviated from HWE. The 3 0 (325)*G-A polymorphism did not deviate from HWE in either of the gender groups in any of the populations.
Strong LD was present between the three markers D12S2510, I1(761)*CA n and 3 0 (325)*G-A in cases and controls in all three populations. LD was less strong in the flanking markers D12S313 and D12S2511. (Table 2 ). Considering consecutive two-marker haplotypes, adjusted for intermarker distance, a significant association was found between carriage of haplotypes including I1(761)*CA n and 3 0 (325)*G-A and MS in men from USA (Po0.001; Figure 2) (P ¼ 0.021). Association was not evident in haplotypes including D12S2510 and D12S2511 (P ¼ 0.596), which contain IL26. No association was found for these haplotypes in women with MS ( Figure 2 ). The associa- tion was not evident in the other two populations although a weak association with MS in Northern Irish women was found for the markers D12S2510 and D12S2511 (P ¼ 0.027; Figure 2 ). In the combined population, accounting for the three populations' independent contributions, the association of the haplotypes defined by the two IFNG markers 3 0 (325)*G-A and I1(761)*CA n became marginally significant (P ¼ 0.059; Figure 2 ) in men.
The analysis of association of the common alleles by carrier status for the two IFNG markers for individual populations is shown in Table 3 . Breslow-Day test for the carrier status of 3 0 (325)*A allele (P ¼ 0.05) and for 3 0 (325)*AA genotype (Po0.01) indicated possible heterogeneity in allele distribution between the three populations, suggesting that the interpretation cannot be solely based on the combined population if the results are not significant in individual populations. The association with susceptibility to MS was strongest in men from USA who are homozygous for 3 0 (325)*A (cases 59% vs controls 28%, Po0.001; OR: 3.74, 95% CI: 1.9-7.37). MS susceptibility was weakly associated in carriers of 3 0 (325)*A (cases 91% vs controls 79%, P ¼ 0.044; OR: 2.58, 95% CI: 0.97-8.08). In Northern Irish men, an association was seen only in men who are carriers of 3 0 (325)*A (cases 89% vs controls 77%, P ¼ 0.019; OR: 2.37, 95% CI: 1.10-5.13). The results were not significant for Belgian men although the odds ratio was in the same direction as the results in the USA and Northern Irish populations (cases 81% vs controls 74%, P ¼ 0.299; OR: 1.50, 95% CI: 0.71-3.26).
The I1(761)*CA 13 allele, which is in strong but incomplete LD with 3 0 (325)*A, tended to be associated with susceptibility to MS in USA men (cases 83% vs controls 69% P ¼ 0.050; OR: 2.22, 95% CI: 0.98-5.40; Table 3 ). Similarly, the I1(761)*CA 12 , which is in strong LD with 3 0 (325)*G, was negatively associated with susceptibility to MS in men from USA (cases 52% vs controls 70%, P ¼ 0.022; OR: 0.46, 95% CI: 0.23-0.90). The marker I1(761)*CA n was not associated with MS in the other populations, even after stratifying by gender. When the populations of men were combined and the analysis was adjusted for populations, carriers for 3 0 (325)*A (P ¼ 0.001; OR: 2.02, 95% CI: 1.31-3.14) and I1(761)*CA No association with susceptibility to MS in women in any of the populations was observed, either individually or when analyzed by successive two-marker haplotypes (Po0.05; Table 3 ). The differences in gender distribution of the carrier status in the combined population were evident only in cases but not controls (Figure 3a ). Among the markers tested, the differences in men and women were strongest for the 3 0 (325)*A allele (P ¼ 0.001; OR: 1.92, 95% CI: 1.29-2.87; Figure 3a) . There was no difference between men and women for being a homozygote for this allele. The difference between men with MS and male controls stratified by population for being a carrier for the 3 0 (325)*A allele is shown in Figure 3b . The association in the combined population is evident in both the Northern Irish and USA populations. The effect persists when the primary progressive cases are removed and bout-onset cases are analyzed independently (Figure 3b ).
Discussion
In this study, we have shown that being a carrier of the A allele of a 3 0 (325)*G-A SNP just 3 0 to IFNG is associated with increased susceptibility to MS in men. This association was significant in two (ie USA and Northern Irish) populations studied, with a similar but nonsignificant trend for the third population from Belgium. The difference in men vs women arises from cases, while the controls have a similar distribution of alleles regardless of gender.
The intragenic marker I1(761)*CA n is associated with susceptibility to MS in men in a well-controlled population-based sample of MS patients from Olmsted County, MN, USA. Analysis of three additional markers that span a 118 kb region flanking IFNG, which were studied in a Sardinian population using family-based association Fisher's exact P-values: *Po0.05, **Po0.01, ***Po0.001.
IFNG, gender and multiple sclerosis OH Kantarci et al methods, 42 suggests that the association is likely within or in the immediate vicinity of the IFNG locus. Our results were similar to those of the Sardinian population for which Goris et al 42 also reported reduced susceptibility to MS in men carrying haplotypes that comprise the I1(761)*CA 12 allele. Given the strong LD between I1(761)*CA n and 3 0 (325)*G-A polymorphisms in our study, the association cannot be attributed to any of the individual markers. However, the association appears to be strongest at the 3 0 (325) SNP. Despite homogeneity in LD through the region, the distribution of genotypes with regard to individual markers was not homogeneous among the three populations studied necessitating some caution in interpretation of the combined population results. While two-marker haplotype analysis revealed association primarily in men from USA, the association for the 3 0 (325) SNP was strongly associated with MS in men both in USA and Northern Ireland; furthermore, the odds ratio was greater than 1.0 for this marker in all three populations. Population heterogeneity regarding microsatellite markers among populations could explain the difference especially regarding the haplotype analysis but this would not invalidate the results since two of the three populations demonstrated a significant association and the third population's results were in the similar direction.
The Belgian study population may be less homogeneous than the Northern Irish (isolated island population) and the American (carefully matched for ethnicity to controls) populations. Also, the MS prevalence in Belgium (88/100 000 in 1991) 44 is lower than in Olmsted County, MN (177/100 000) 45 and Northern Ireland (168/ 100 000), 46 and genetic load may be higher in populations with higher prevalence. Ultimately, lesser homogeneity and different genetic loading may affect the power to detect a weak effect in complex disorders. It is also possible that men who have the haplotype with CA 13 /A alleles have greater susceptibility to MS from a yet to be identified additional susceptibility factor present in the MN and Northern Irish, but not Belgian, populations. Goris et al 42 recently confirmed that a protective effect of the haplotype including I1(761)*CA 12 from MS in men is evident in Sardinians only if they also lack the high-risk HLA*DR3 or HLA*DR4 genotypes. Increased MS susceptibility to HLA*DR3 or HLA*DR4 carriers is present only in Sardinians, whereas HLA*DR2 carriers have increased susceptibility to MS in other European populations. 47 IFNg production may be HLA*DR dependent. HLA DR3, 4, 5 and 7 are associated with low, while DR1, 2 and 6 are associated with high IFNg production. 48 Whether there is any direct or indirect interaction between HLA*DR alleles and IFNG polymorphisms remains to be elucidated.
Other groups have also studied the I1(761)*CA n polymorphism for association with MS and other multifactorial diseases. 49 In Sweden, an initial weak association with susceptibility and linkage to MS was detected. 37, 39 In a large study from Sweden, Dai et al 41 did not find an association between IFNG polymorphisms with either susceptibility to and severity of MS or with mRNA levels of IFNg. In a transmission disequilibrium-based study from France, 40 there was significant undertransmission of I1(761)*CA 12 to patients with MS (transmitted: N ¼ 34; nontransmitted: N ¼ 60) when compared to I1(761)*CA 13 allele (transmitted: N ¼ 62; nontransmitted: N ¼ 44), supporting our finding even though gender stratification was omitted. German and Italian MS populations did not manifest the gender bias observed in our study. 39 As discussed for the Belgian population differences in genetic loading, heterogeneity of cases and controls and the indirect effects of these two factors on power may account for some of these differences. Interestingly, the IFNG intron 1 CA polymorphism was shown to be a modifier gene in tuberous sclerosis-2; the CA 12 allele is protective against kidney angiomyolipomas, particularly in men. 50 This finding suggests that IFNG may be relevant to gender-associated disease manifestations beyond MS. Other microsatellites in this general region have been associated with susceptibility to rheumatoid arthritis in women. 51 Pravica et al 52 and others have shown that the I1(761)*CA 12 allele is associated with increased expression of IFNg mainly in homozygotes, although a trend toward increased expression was observed in heterozygotes, findings confirmed by others. 53 allele is in strong LD with I1(759)*T. Homozygosity for the I1(759)*A allele is associated with a 3.8-fold increase in risk of tuberculosis in Spain. Stimulated production of IFNg by peripheral mononuclear cells from I1(759)*A homozygotes is depressed compared with I1(759)*T carriers. 57 This polymorphism was also found to be strongly associated with susceptibility to tuberculosis in South Africa both in populationbased and family-based association studies. 58 LD between these markers and, as demonstrated in our study, between I1(761)*CA n and the 3 0 (325)*G-A SNP, may lend a functional relevance to our observations. Alternatively, a yet to be identified polymorphism in LD with the relevant haplotypes as described could be responsible for the effect.
The apparent protective effect of CA 12 /G haplotype, which would be expected to be associated with higher IFNg expression, seems to conflict with the hypothesis that higher IFNg expression leads to an increased Th-1 cell response and consequently greater susceptibility to MS. 59 On the other hand, some effects of IFNg-related inflammation such as inhibition of the accumulation of activated T cells by limiting antigen-induced proliferation and/or by enhancing apoptosis can actually be protective in autoimmune disorders as recently discussed by O'Shea and Paul 60 and Martino et al. 61 Recent evidence by Pelfrey et al 26 and Nguyen et al 27 suggests that there is stronger Th-1/Th-2 bias in women than men with MS. The difference in frequency of the alleles between men and women may also reflect interaction between the disease, the genotype and gender, because the differences in genotype frequency are not evident in the controls. A functional explanation for how the IFNG polymorphism associations we revealed might influence gender bias in susceptibility to MS might be sought in hormonal effects on IFNg production. Estrogen (17-betaestradiol) markedly increases transcription from the IFNg promoter and the level of dehydroepiandrosterone correlates with IFNg secretion. 62, 63 Estriol treatment of nonpregnant women with MS decreases IFNg levels and suppresses the development of gadolinium enhancing lesions in the brain. 64 No evidence currently exists to link the current polymorphisms with this effect of the sex steroids on IFNg expression.
IFNg expression and effects vary by gender in a variety of experimental models and disease states other than MS. Myelin basic protein (MBP)-specific T cells from male mice were shown to be less encephalitogenic than MBPspecific cells from female mice in EAE. 65 In that study, IL-12 and IFNg production were lower in males than in females after antigen-specific stimulation of draining lymph node cells, while the IL-10 and IL-4 production were similar. In the predominantly Th-2 cell-mediated Leishmania mexicana infection, female mice known to be resistant to infection express more IFNg in lymph nodes than male mice. 66 These findings suggest a predominant Th-1 response in females, which is protective in this instance. Female mice produce more IFNg than male mice in picornavirus and encephalomyocarditis virus infections and in response to PPD II in BCG-sensitized mice. [67] [68] [69] [70] IFNg deficiency markedly decreases atherosclerotic lesions in male mice, but has no effect in female mice. 71 Male IFNg or IFNg receptor knockout mice infected with herpes simplex virus type-1 have a higher frequency of reactivation and a higher associated mortality than wild-type mice, whereas there is no difference between knockout and wild-type females. 72 Taken together with previous studies, our study provides further evidence that there is an association between IFNG polymorphisms and susceptibility to sporadic MS. Genetic variation in IFNg may in part account for gender differences in susceptibility to MS.
Patients and methods

Patient populations
The data set consisted of three independently ascertained populations of patients and controls from USA, Northern Ireland and Belgium. The demographic details of these populations are illustrated in Table 1 . The patient population from MN was unique in that it consisted of 221 patients (64 men and 157 women) representing 79% ascertainment of two overlapping population-based prevalence cohorts from 1991 73, 74 from Olmsted County, MN. A total of 442 controls (128 men and 314 women) matched for ethnicity, age and gender were selected from 4000 Mayo Clinic patients from whom DNA samples had been obtained. The details of the patient population and ethnicity matching are described elsewhere. 75 The population from Northern Ireland consisted of 432 cases (147 men and 285 women) and 205 controls (98 men and 107 women) and the population from Belgium consisted of 208 cases (82 men and 126 women) and 196 controls (114 men and 82 women). Controls from these populations were clinic-based and not specifically matched to cases for ethnicity, gender and age. The institutional review boards at all three participating institutions approved the study.
Selection of markers and genotyping
The same markers were selected as those that had been studied in the previous studies in Sardinia and MN. 42, 43, 76 We evaluated two markers within or immediately adjacent to IFNG, a CA repeat microsatellite in intron 1 [I1(761)*CA n ] and an SNP just 3 0 of the poly A site [3 0 (325)*G-A] (rs#2069727); these markers are identified herein according to their position relative to the first base of the exon or intron in which they are found. We also studied three flanking microsatellite markers spanning a 118 kb region around IFNG that includes IL26 (D12S313, D12S2510 and D12S2511 from centromere to telomere). The microsatellite markers were sized by automated sequencing utilizing DNA sequencers (Applied Biosystems, ABI3100 model). The SNP was analyzed by a fluorescence polarization-based single base extension method (Analyst HT, Molecular Devices). 77 Equivocal samples are studied with a primer in the reverse orientation on the amplicon to ensure agreement with results of the other primer. The relative location of the markers studied is shown in Figure 1 .
Statistical analysis LD in cases and controls through the region containing IFNG was analyzed using the D 0 measure. We studied association for individual markers by genotype; differences in carrier frequencies for cases and controls, stratified by gender, were assessed using Fisher's exact statistics for contingency tables. The Breslow-Day test was used to first check for homogeneity of the odds ratios for the three populations, and then the CochranMantel-Haenzel statistic was used to combine results of the three populations. Note that the odds ratio confidence limits are conservative and do not correspond exactly to the P-values listed. Haplotype frequencies were imputed for individuals with ambiguous haplotypes by an expectation-maximization algorithm and compared between cases and controls using a test for associations between traits and haplotypes where phase is ambiguous using the haplo.score function within Splus. 78 Simulated P-values were estimated to help eliminate spurious significant results that may result from multiple testing. 78 Consecutive two-marker haplotypes were used to further compare cases and controls using the max-stat statistic and the corresponding permutation P-values. Haplotypes with expected frequencies of less than 5% were removed from the analyses to increase model stability. All analysis was completed using the SAS 79 and Splus software packages. 80 
